Research programme: inflammation therapy - Pharmacopeia
Alternative Names: PS 826957Latest Information Update: 12 Oct 2009
Price :
$50 *
At a glance
- Originator Pharmacopeia Drug Discovery
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 12 Oct 2009 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
- 11 Jul 2007 Left active as this is a core focus of the company and research is probably ongoing